Search Within

Gastrointestinal Oncology Service

Formats
  1. Journal Article (2349)
  2. Meeting Abstract (1870)
  3. Review (150)
  4. Book Section (127)
  5. Editorial (100)
  6. Guidelines (39)
  7. Correspondence (34)
  8. Conference Paper (24)
  9. Miscellaneous (22)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Solid Tumor Oncology Division (4744)
  2. Department of Medicine (4742)
  3. Center for Pancreatic Cancer Research (2312)
  4. Surgery (1065)
  5. Survivorship Research (1013)
  6. Epidemiology and Biostatistics (842)

More Groups

People
  1. Eileen O'Reilly (803)
  2. Leonard Saltz (796)
  3. Ghassan Abou-Alfa (583)
  4. Nancy Kemeny (545)
  5. David Kelsen (538)
  6. David Ilson (443)

More People

Years
  1. 2025 (219)
  2. 2024 (309)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1290)
  2. Annals of Oncology (331)
  3. Annals of Surgical Oncology (147)
  4. Cancer (128)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1379)
  2. Oxford University Press (462)
  3. Elsevier Inc. (408)
  4. Springer (320)
  5. American Association for Cancer Research (281)
  6. Wiley Blackwell (241)

More Publishers

Results (4744)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2–, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Ajani, J. A.; Lordick, F.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; Shah, M. A.; Van Cutsem, E.; Xu, R. H.; Aprile, G.; Xu, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)
    Meeting Abstract

    Chan, J.; Geyer, S.; Ou, F. S.; Knopp, M.; Behr, S.; Zemla, T.; Acoba, J.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study
    Meeting Abstract

    Shiu, K. K.; André, T.; Kim, T. W.; Vittrup Jensen, B.; Jensen, L. H.; Punt, C. J. A.; Smith, D.; Garcia-Carbonero, R.; Alcaide-Garcia, J.; Gibbs, P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Chemotherapy priming leads to hypermutability and immune surveillance in colorectal cancer
    Meeting Abstract

    Vitiello, P. P.; Chilà, R.; Battuello, P.; Battaglieri, V.; Amodio, V.; Grasso, G.; Rospo, G.; Lamba, S.; Pisati, F.; Rousseau, B. J. C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
    Meeting Abstract

    Varghese, A. M.; Golan, T.; Schattner, M.; Ang, C.; Gutierrez, M.; Passhak, M.; Geva, R.; Yarom, N.; Ligresti, R.; Khamaysi, I.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Health-related quality of life with nalirifox versus nabpaclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): EORTC QLQ-C30 results from the NAPOLI 3 trial
    Meeting Abstract

    Melisi, D.; Macarulla, T.; de la Fouchardiere, C.; Cid, R. A. P.; Chandana, S.; Dean, A.; Kiss, I.; Lee, W.; Goetze, T. O.; Van Cutsem, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Schram, A.; Macarulla, T.; Cleary, J.; Neuzillet, C.; Arnold, D.; Reiss, K. A.; Bekaii-Saab, T.; Rodon, J.; Goto, K.; Rha, S. Y.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
    Meeting Abstract

    Janjigian, Y. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Weber, P. E. Y.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
    Meeting Abstract

    Ku, G.; Shen, L.; Klempner, S. J.; Pan, H.; Kratz, J.; Liang, X.; Deng, Y.; Kim, S.; Wang, Z.; Feller, L.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations
    Meeting Abstract

    Pelster, M. S.; Yaeger, R.; Klempner, S. J.; Ou, S. H. I.; Spira, A. I.; Jänne, P. A.; Uboha, N. V.; Gaffar, Y. A.; Newman, G.; Paweletz, C. P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save